Abiopharma

🔍 Young Jonathan (Executive)

Company: Akero Therapeutics, Inc. (AKRO)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Acquired 12,500 shares of Common Stock at $21.1 per share (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: false | shares_owned_after: 209,984.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 9,700 shares of Common Stock at $45.776 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 200,284.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 2,739 shares of Common Stock at $47.136 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 197,545.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 61 shares of Common Stock at $47.58 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: false | shares_owned_after: 197,484.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: H | nature_of_ownership: By EA Irrevocable Trust | shares_owned_after: 20,000.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: H | nature_of_ownership: By CM Irrevocable Trust | shares_owned_after: 20,000.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-09-02 | Code: H | nature_of_ownership: By JL Irrevocable Trust | shares_owned_after: 20,000.00 | Footnotes: F2
• Sold 82,482 shares of Stock Option (Right to Buy) at $21.1 per share (Derivative)
  Date: 2025-09-02 | Code: M | Expires: 2031-12-07 | equity_swap_involved: false | shares_owned_after: 57,482.00 | transaction_form_type: 4 | Footnotes: F1, F5

Footnotes:

• F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025, previously adopted by the Reporting Person.
• F2: These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.48 to $46.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
• F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.54 to $47.54, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
• F5: This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2021